Hepatitis C Virus Detection: Methods, Samples, and Clinical Applications

Hepatitis C virus (HCV) detection is the laboratory process of identifying HCV infection through serological screening for anti-HCV antibodies and molecular testing for viral RNA. Accurate and timely HCV detection is essential for early diagnosis, guiding direct-acting antiviral therapy, and preventing progression to cirrhosis and liver cancer. This technical guide explains the sample types, testing items, analytical methods, and clinical applications involved in modern HCV testing.

Technical Overview

Hepatitis C virus (HCV) is an enveloped, positive-sense, single-stranded RNA virus belonging to the genus Hepacivirus within the family Flaviviridae. Its genome of approximately 9.6 kilobases encodes structural proteins (Core, E1, E2) and non-structural proteins (NS3, NS4A, NS4B, NS5A, NS5B), which serve as key antigenic and drug-target markers in laboratory assays. HCV is classified into seven major genotypes and more than 60 subtypes, a diversity that historically influenced therapeutic choices and continues to affect vaccine development.

HCV is transmitted primarily through blood-to-blood contact, and chronic infection often progresses silently over decades toward cirrhosis and hepatocellular carcinoma. The World Health Organization estimates that roughly 50 million people worldwide live with chronic HCV infection, with nearly 300,000 HCV-related deaths each year. Current clinical guidelines recommend a two-step diagnostic algorithm: initial serological screening for anti-HCV antibodies, followed by nucleic acid testing (NAT) for HCV RNA to confirm active viremia. Because curative direct-acting antiviral (DAA) therapy achieves sustained virologic response rates above 95%, reliable laboratory detection is the gateway to global hepatitis C elimination programs.

Testing Samples

Serum

Serum is the standard matrix for anti-HCV antibody screening by enzyme immunoassay (EIA) and chemiluminescent microparticle immunoassay (CMIA). Venous blood is collected in a plain tube, allowed to clot completely, and centrifuged to separate the serum. Serum specimens remain stable at 2–8 °C for up to one week and can be stored at −20 °C or below for longer periods. Serum is also suitable for HCV core antigen testing on validated platforms.

Plasma

Plasma collected in EDTA anticoagulant tubes is the preferred specimen for quantitative HCV RNA assays and is widely used in nucleic acid screening of donated blood. To minimize RNA degradation, plasma should be separated from cells within 4–6 hours of collection; if testing is delayed, samples should be frozen at −70 °C. Heparinized tubes must be avoided because heparin inhibits polymerase chain reaction amplification and may cause false-negative results.

Whole Blood and Dried Blood Spots

Capillary whole blood obtained by fingerstick supports rapid point-of-care antibody tests. Dried blood spots (DBS) collected onto filter paper are an accepted alternative in resource-limited settings, harm-reduction programs, and remote regions, because they simplify logistics and eliminate the cold chain. DBS support both antibody and RNA detection, albeit with somewhat lower analytical sensitivity than liquid plasma, which must be considered when interpreting negative results in low-viremic patients.

Testing Items

Depending on the clinical objective, HCV detection comprises the following laboratory items:

• Anti-HCV antibodies: the screening marker indicating exposure to HCV; it cannot distinguish active infection from resolved past infection.
• HCV core antigen: a capsid protein marker that correlates closely with RNA levels and serves as a lower-cost surrogate for confirming viremia.
• HCV RNA, qualitative and quantitative: the reference standard for diagnosing current infection and for monitoring viral load, reported in IU/mL.
• HCV genotype and subtype: determination of viral classification, historically used to select DAA regimens and treatment duration.
• Resistance-associated substitutions (RAS): sequencing of the NS3, NS5A, and NS5B regions in patients who experienced prior DAA treatment failure.

Testing Methods

Serological Assay Methods

Third- and fourth-generation EIAs and CLIAs employ recombinant and synthetic antigens derived from the Core, NS3, NS4, and NS5 regions, achieving sensitivity and specificity exceeding 99% in immunocompetent populations. Rapid diagnostic tests based on immunochromatography deliver results within 15–30 minutes from fingerstick whole blood, enabling point-of-care screening in community outreach and harm-reduction settings. Historically, reactive screening results were confirmed by recombinant immunoblot assay (RIBA); however, RIBA has been discontinued and replaced by molecular confirmation with HCV RNA or core antigen testing. False-negative serology may occur during early acute infection, in severe immunosuppression, hemodialysis patients, and agammaglobulinemia, requiring RNA testing when clinical suspicion is high.

Molecular Assay Methods

Quantitative real-time reverse transcription PCR (RT-qPCR) and transcription-mediated amplification (TMA) are the mainstream platforms for HCV RNA quantification, offering limits of detection of approximately 10–15 IU/mL and broad linear ranges extending to 100 million IU/mL. Qualitative ultrasensitive NAT is used to confirm cure, defined as undetectable RNA at 12 weeks after treatment completion (SVR12). Genotyping is performed using reverse-hybridization line-probe assays (LiPA), Sanger sequencing, or next-generation sequencing of viral genomic regions. Molecular methods represent the gold standard for diagnosing acute HCV because RNA becomes detectable one to three weeks after exposure, well before seroconversion.

Antigen-Based Methods

Quantitative immunoassays for total HCV core antigen provide a cost-effective alternative to NAT for confirming viremia in antibody-positive individuals. Core antigen levels parallel RNA concentrations across a wide dynamic range, with analytical detection limits corresponding to roughly 1,000–3,000 IU/mL of RNA. This reduced sensitivity makes core antigen testing unsuitable for end-of-treatment response assessment, but it remains valuable in settings lacking molecular infrastructure, particularly in low- and middle-income countries pursuing simplified test-and-treat strategies.

Applications

• Blood safety: routine NAT and antibody screening of donated blood, plasma derivatives, and tissue or organ donors.
• Diagnosis: confirmation of chronic HCV infection in anti-HCV reactive individuals and detection of acute infection in high-risk exposures.
• Pre-treatment evaluation: baseline viral load quantification, genotyping where regimen-relevant, and linkage to fibrosis assessment.
• Therapy monitoring: viral load measurement during treatment and SVR12 testing to confirm cure.
• Population screening: people who inject drugs, hemodialysis patients, persons with HIV coinfection, incarcerated individuals, and adults born between 1945 and 1965 in targeted birth-cohort programs.
• Perinatal follow-up: diagnostic evaluation of infants born to HCV-infected mothers using RNA testing after one to two months of age.
• Public health surveillance: epidemiological monitoring and evaluation of progress toward WHO hepatitis C elimination targets.

FAQ

What is the window period for HCV detection?

HCV RNA becomes detectable approximately one to three weeks after exposure, whereas anti-HCV antibodies typically appear eight to eleven weeks after exposure. For suspected recent infection, guidelines recommend HCV RNA testing at four to six weeks after exposure, followed by repeat antibody testing if initial results are negative.

Does a reactive anti-HCV result mean active hepatitis C infection?

Not necessarily. A reactive antibody result only indicates prior exposure, and approximately 15–45% of infected individuals spontaneously clear the virus while remaining antibody-positive. Active infection must be confirmed by detecting HCV RNA or core antigen before treatment is initiated.

How is cure confirmed after antiviral treatment?

Cure is defined as sustained virologic response at week 12 after completing therapy (SVR12), documented by an undetectable HCV RNA result using an assay with a limit of detection of 15 IU/mL or lower.

Which sample type is preferred for viral load testing?

EDTA plasma is the preferred specimen for quantitative RNA assays. Samples should be processed within 4–6 hours of collection, heparin tubes must be avoided, and specimens awaiting testing should be stored frozen at −70 °C to preserve RNA integrity.

Can standard antibody tests diagnose HCV infection in newborns?

No. Maternal IgG antibodies cross the placenta and may persist in infants for up to 18 months, causing uninformative positive results. Pediatric diagnosis requires HCV RNA testing after one to two months of age or deferred antibody testing after 18 months.